Literature DB >> 12860842

The putative role of isoprostanes in human cardiovascular physiology and disease: following the fingerprints.

J-L Cracowski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12860842      PMCID： PMC1767775          DOI： 10.1136/heart.89.8.821

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  17 in total

Review 1.  Platelet-active drugs : the relationships among dose, effectiveness, and side effects.

Authors:  C Patrono; B Coller; J E Dalen; G A FitzGerald; V Fuster; M Gent; J Hirsh; G Roth
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

2.  Involvement of TP and EP3 receptors in vasoconstrictor responses to isoprostanes in pulmonary vasculature.

Authors:  Luke J Janssen; Tracy Tazzeo
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

3.  Increased formation of F(2)-isoprostanes in patients with severe heart failure.

Authors:  J L Cracowski; F Tremel; C Marpeau; J P Baguet; F Stanke-Labesque; J M Mallion; G Bessard
Journal:  Heart       Date:  2000-10       Impact factor: 5.994

4.  Isoprostaglandin E2 type-III (8-iso-prostaglandin E2) evoked contractions in the human internal mammary artery.

Authors:  J L Cracowski; P Devillier; O Chavanon; F A Sietchiping-Nzepa; F Stanke-Labesque; G Bessard
Journal:  Life Sci       Date:  2001-04-13       Impact factor: 5.037

5.  Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine.

Authors:  H Li; J A Lawson; M Reilly; M Adiyaman; S W Hwang; J Rokach; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

Review 6.  Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo.

Authors:  L J Roberts; J D Morrow
Journal:  Free Radic Biol Med       Date:  2000-02-15       Impact factor: 7.376

7.  The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis.

Authors:  A J Cayatte; Y Du; J Oliver-Krasinski; G Lavielle; T J Verbeuren; R A Cohen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-07       Impact factor: 8.311

8.  Thromboxane A2 signalling in humans: a 'Tail' of two receptors.

Authors:  B T Kinsella
Journal:  Biochem Soc Trans       Date:  2001-11       Impact factor: 5.407

9.  The 5-series F(2)-isoprostanes possess no vasomotor effects in the rat thoracic aorta, the human internal mammary artery and the human saphenous vein.

Authors:  Stéphanie Marlière; Jean-Luc Cracowski; Thierry Durand; Olivier Chavanon; Janine Bessard; Alexandre Guy; Françoise Stanke-Labesque; Jean-Claude Rossi; Germain Bessard
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

10.  Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice.

Authors:  D Praticò; R K Tangirala; D J Rader; J Rokach; G A FitzGerald
Journal:  Nat Med       Date:  1998-10       Impact factor: 53.440
View more
  3 in total

1.  B1-phytoprostanes trigger plant defense and detoxification responses.

Authors:  Christiane Loeffler; Susanne Berger; Alexandre Guy; Thierry Durand; Gerhard Bringmann; Michael Dreyer; Uta von Rad; Jörg Durner; Martin J Mueller
Journal:  Plant Physiol       Date:  2004-12-23       Impact factor: 8.340

Review 2.  Platelet function and Isoprostane biology. Should isoprostanes be the newest member of the orphan-ligand family?

Authors:  Harold J Ting; Fadi T Khasawneh
Journal:  J Biomed Sci       Date:  2010-04-06       Impact factor: 8.410

3.  24-Hour ambulatory blood pressure associates inversely with prostaglandin F(2α), interleukin-6 and F(2)-isoprostane formation in a Swedish population of older men.

Authors:  Johanna Helmersson-Karlqvist; Kristina Björklund-Bodegård; Anders Larsson; Samar Basu
Journal:  Int J Clin Exp Med       Date:  2012-04-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.